Breast Cancer Version 3.2014

Authors:
William J. Gradishar
Search for other papers by William J. Gradishar in
Current site
Google Scholar
PubMed Close
 MD
,
Benjamin O. Anderson
Search for other papers by Benjamin O. Anderson in
Current site
Google Scholar
PubMed Close
 MD
,
Sarah L. Blair
Search for other papers by Sarah L. Blair in
Current site
Google Scholar
PubMed Close
 MD
,
Harold J. Burstein
Search for other papers by Harold J. Burstein in
Current site
Google Scholar
PubMed Close
 MD, PhD
,
Amy Cyr
Search for other papers by Amy Cyr in
Current site
Google Scholar
PubMed Close
 MD
,
Anthony D. Elias
Search for other papers by Anthony D. Elias in
Current site
Google Scholar
PubMed Close
 MD
,
William B. Farrar
Search for other papers by William B. Farrar in
Current site
Google Scholar
PubMed Close
 MD
,
Andres Forero
Search for other papers by Andres Forero in
Current site
Google Scholar
PubMed Close
 MD
,
Sharon Hermes Giordano
Search for other papers by Sharon Hermes Giordano in
Current site
Google Scholar
PubMed Close
 MD, MPH
,
Lori J. Goldstein
Search for other papers by Lori J. Goldstein in
Current site
Google Scholar
PubMed Close
 MD
,
Daniel F. Hayes
Search for other papers by Daniel F. Hayes in
Current site
Google Scholar
PubMed Close
 MD
,
Clifford A. Hudis
Search for other papers by Clifford A. Hudis in
Current site
Google Scholar
PubMed Close
 MD
,
Steven J. Isakoff
Search for other papers by Steven J. Isakoff in
Current site
Google Scholar
PubMed Close
 MD, PhD
,
Britt-Marie E. Ljung
Search for other papers by Britt-Marie E. Ljung in
Current site
Google Scholar
PubMed Close
 MD
,
P. Kelly Marcom
Search for other papers by P. Kelly Marcom in
Current site
Google Scholar
PubMed Close
 MD
,
Ingrid A. Mayer
Search for other papers by Ingrid A. Mayer in
Current site
Google Scholar
PubMed Close
 MD
,
Beryl McCormick
Search for other papers by Beryl McCormick in
Current site
Google Scholar
PubMed Close
 MD
,
Robert S. Miller
Search for other papers by Robert S. Miller in
Current site
Google Scholar
PubMed Close
 MD
,
Mark Pegram
Search for other papers by Mark Pegram in
Current site
Google Scholar
PubMed Close
 MD
,
Lori J. Pierce
Search for other papers by Lori J. Pierce in
Current site
Google Scholar
PubMed Close
 MD
,
Elizabeth C. Reed
Search for other papers by Elizabeth C. Reed in
Current site
Google Scholar
PubMed Close
 MD
,
Kilian E. Salerno
Search for other papers by Kilian E. Salerno in
Current site
Google Scholar
PubMed Close
 MD
,
Lee S. Schwartzberg
Search for other papers by Lee S. Schwartzberg in
Current site
Google Scholar
PubMed Close
 MD, FACP
,
Mary Lou Smith
Search for other papers by Mary Lou Smith in
Current site
Google Scholar
PubMed Close
 JD, MBA
,
Hatem Soliman
Search for other papers by Hatem Soliman in
Current site
Google Scholar
PubMed Close
 MD
,
George Somlo
Search for other papers by George Somlo in
Current site
Google Scholar
PubMed Close
 MD
,
John H. Ward
Search for other papers by John H. Ward in
Current site
Google Scholar
PubMed Close
 MD
,
Antonio C. Wolff
Search for other papers by Antonio C. Wolff in
Current site
Google Scholar
PubMed Close
 MD
,
Richard Zellars
Search for other papers by Richard Zellars in
Current site
Google Scholar
PubMed Close
 MD
,
Dorothy A. Shead
Search for other papers by Dorothy A. Shead in
Current site
Google Scholar
PubMed Close
 MS
, and
Rashmi Kumar
Search for other papers by Rashmi Kumar in
Current site
Google Scholar
PubMed Close
 PhD
Volume/Issue:
Volume 12: Issue 4
Online Publication Date:
Apr 2014
DOI:
https://doi.org/10.6004/jnccn.2014.0058
Restricted access

Breast cancer is the most common malignancy in women in the United States and is second only to lung cancer as a cause of cancer death. The overall management of breast cancer includes the treatment of local disease with surgery, radiation therapy, or both, and the treatment of systemic disease with cytotoxic chemotherapy, endocrine therapy, biologic therapy, or combinations of these. The NCCN Guidelines specific to management of large clinical stage II and III tumors are discussed in this article. These guidelines are the work of the members of the NCCN Breast Cancer Panel. Expert medical clinical judgment is required to apply these guidelines in the context of an individual patient to provide optimal care. Although not stated at every decision point of the guidelines, patient participation in prospective clinical trials is the preferred option of treatment for all stages of breast cancer.

  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9–29.

  • 2.

    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687–1717.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212–236.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Berry DA, Cronin KA, Plevritis SK et al.. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005;353:1784–1792.

  • 5.

    White J, Morrow M, Moughan J et al.. Compliance with breast-conservation standards for patients with early-stage breast carcinoma. Cancer 2003;97:893–904.

  • 6.

    Wilkinson NW, Shahryarinejad A, Winston JS et al.. Concordance with breast cancer pathology reporting practice guidelines. J Am Coll Surg 2003;196:38–-43.

  • 7.

    Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11:155–168.

  • 8.

    Rhodes A, Jasani B, Barnes DM et al.. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol 2000;53:125–130.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Rudiger T, Hofler H, Kreipe HH et al.. Quality assurance in immunohistochemistry: results of an interlaboratory trial involving 172 pathologists. Am J Surg Pathol 2002;26:873–882.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Allred DC, Carlson RW, Berry DA et al.. NCCN Task Force Report: estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry. J Natl Compr Canc Netw 2009;7(Suppl 6):S1–21; quiz S22-23.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Hammond MEH, Hayes DF, Dowsett M et al.. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;28:2784–2795.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Hammond ME. ASCO-CAP guidelines for breast predictive factor testing: an update. Appl Immunohistochem Mol Morphol 2011;19:499–500.

  • 13.

    Wang S, Saboorian MH, Frenkel E et al.. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. J Clin Pathol 2000;53:374–381.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Dybdal N, Leiberman G, Anderson S et al.. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res Treat 2005;93:3–11.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Paik S, Bryant J, Tan-Chiu E et al.. Real-world performance of HER2 testing—National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002;94:852–854.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Paik S, Tan-Chiu E, Bryant J et al.. Successful quality assurance program for HER2 testing in the NSABP trial for Herceptin [abstract]. Breast Cancer Res Treat 2002;76(Suppl):Abstract S31.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Perez EA, Suman VJ, Davidson NE et al.. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 Intergroup adjuvant trial. J Clin Oncol 2006;24:3032–3038.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Tubbs RR, Pettay JD, Roche PC et al.. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 2001;19:2714–2721.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Press MF, Sauter G, Bernstein L et al.. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 2005;11:6598–6607.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Wolff AC, Hammond ME, Hicks DG et al.. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013;31:3997–4013.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Wolff AC, Hammond ME, Hicks DG et al.. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline update. Arch Pathol Lab Med 2014;138:241–256.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med 2002;137:678–687.

  • 23.

    Giordano SH, Valero V, Buzdar AU, Hortobagyi GN. Efficacy of anastrozole in male breast cancer. Am J Clin Oncol 2002;25:235–237.

  • 24.

    Esserman L. Integration of imaging in the management of breast cancer. J Clin Oncol 2005;23:1601–1602.

  • 25.

    Gundry KR. The application of breast MRI in staging and screening for breast cancer. Oncology (Williston Park) 2005;19:159–169.

  • 26.

    Houssami N, Ciatto S, Macaskill P et al.. Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer. J Clin Oncol 2008;26:3248–3258.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Lehman CD, DeMartini W, Anderson BO, Edge SB. Indications for breast MRI in the patient with newly diagnosed breast cancer. J Natl Compr Canc Netw 2009;7:193–201.

  • 28.

    Fischer U, Zachariae O, Baum F et al.. The influence of preoperative MRI of the breasts on recurrence rate in patients with breast cancer. Eur Radiol 2004;14:1725–1731.

  • 29.

    Solin LJ, Orel SG, Hwang WT et al.. Relationship of breast magnetic resonance imaging to outcome after breast-conservation treatment with radiation for women with early-stage invasive breast carcinoma or ductal carcinoma in situ. J Clin Oncol 2008;26:386–391.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Members of the Breast Cancer Disease Site Group. Baseline staging tests in primary breast cancer. Hamm C, Tey R, reviewers. Toronto (ON): Cancer Care Ontario; 2011 Nov 1 [Endorsed 2011 Oct 11]. Program in Evidence-based Care Evidence-Based Series No.: 1-14 Version 2.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Puglisi F, Follador A, Minisini AM et al.. Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indications. Ann Oncol 2005;16:263–266.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Aukema TS, Straver ME, Peeters MJ et al.. Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer. Eur J Cancer 2010;46:3205–3210.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Fuster D, Duch J, Paredes P et al.. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol 2008;26:4746–4751.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34.

    Groheux D, Moretti JL, Baillet G et al.. Effect of (18)F-FDG PET/CT imaging in patients with clinical stage II and III breast cancer. Int J Radiat Oncol Biol Phys 2008;71:695–704.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35.

    Podoloff DA, Advani RH, Allred C et al.. NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw 2007;5(Suppl 1):S1–22; quiz 23-24.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36.

    Rosen EL, Eubank WB, Mankoff DA. FDG PET, PET/CT, and breast cancer imaging. Radiographics 2007;27(Suppl 1):S215–229.

  • 37.

    van der Hoeven JJM, Krak NC, Hoekstra OS et al.. 18F(2-fluoro-2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer. J Clin Oncol 2004;22:1253–1259.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38.

    Niikura N, Costelloe CM, Madewell JE et al.. FDG-PET/CT compared with conventional imaging in the detection of distant metastases of primary breast cancer. Oncologist 2011;16:1111–1119.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Morris PG, Lynch C, Feeney JN et al.. Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer. J Clin Oncol 2010;28:3154–3159.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    Alessio AM, Kinahan PE, Cheng PM et al.. PET/CT scanner instrumentation, challenges, and solutions. Radiol Clin North Am 2004;42:1017–1032.

  • 41.

    Wong TZ, Paulson EK, Nelson RC et al.. Practical approach to diagnostic CT combined with PET. AJR Am J Roentgenol 2007;188:622–629.

  • 42.

    Kranick JA, Schaefer C, Rowell S et al.. Is pregnancy after breast cancer safe? Breast J 2010;16:404–411.

  • 43.

    Cruz MR, Prestes JC, Gimenes DL, Fanelli MF. Fertility preservation in women with breast cancer undergoing adjuvant chemotherapy: a systematic review. Fertil Steril 2010;94:138–143.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44.

    Dunn L, Fox KR. Techniques for fertility preservation in patients with breast cancer. Curr Opin Obstet Gynecol 2009;21:68–73.

  • 45.

    Oktem O, Oktay K. Fertility preservation for breast cancer patients. Semin Reprod Med 2009;27:486–492.

  • 46.

    Redig AJ, Brannigan R, Stryker SJ et al.. Incorporating fertility preservation into the care of young oncology patients. Cancer 2011;117:4–10.

  • 47.

    Lee S, Ozkavukcu S, Heytens E et al.. Value of early referral to fertility preservation in young women with breast cancer. J Clin Oncol 2010;28:4683–4686.

  • 48.

    Lobo RA. Potential options for preservation of fertility in women. N Engl J Med 2005;353:64–73.

  • 49.

    Sukumvanich P, Case LD, Van Zee K et al.. Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment: a prospective study. Cancer 2010;116:3102–3111.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50.

    Peate M, Meiser B, Friedlander M et al.. It’s now or never: fertility-related knowledge, decision-making preferences, and treatment intentions in young women with breast cancer—an Australian fertility decision aid collaborative group study. J Clin Oncol 2011;29:1670–1677.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 51.

    Alkuwari E, Auger M. Accuracy of fine-needle aspiration cytology of axillary lymph nodes in breast cancer patients: a study of 115 cases with cytologic-histologic correlation. Cancer 2008;114:89–93.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 52.

    Classe JM, Bordes V, Campion L et al.. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol 2009;27:726–732.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53.

    Hunt KK, Yi M, Mittendorf EA et al.. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg 2009;250:558–566.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 54.

    Kuehn T, Vogl FD, Helms G et al.. Sentinel-node biopsy for axillary staging in breast cancer: results from a large prospective German multi-institutional trial. Eur J Surg Oncol 2004;30:252–259.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 55.

    Kuehn T, Bauerfeind I, Fehm T et al.. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol 2013;14:609–618.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56.

    Boughey JC, Suman VJ, Mittendorf EA et al.. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 2013;310:1455–1461.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 57.

    Fisher B, Bryant J, Wolmark N et al.. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672–2685.

  • 58.

    Bear HD, Anderson S, Smith RE et al.. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006;24:2019–2027.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 59.

    Hortobagyi GN, Singletary SE, Strom EA. Treatment of locally advanced and inflammatory breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the Breast. Philadelphia: Lippincott Williams & Wilkins; 2004:645–660.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 60.

    Hudis C, Modi S. Preoperative chemotherapy for breast cancer: miracle or mirage? JAMA 2007;298:2665–2667.

  • 61.

    Buzdar AU, Ibrahim NK, Francis D et al.. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23:3676–3685.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 62.

    Buzdar AU, Valero V, Ibrahim NK et al.. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007;13:228–233.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 63.

    Untch M, Loibl S, Bischoff J et al.. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 2012;13:135–144.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 64.

    Baselga J, Bradbury I, Eidtmann H et al.. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012;379:633–640.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 65.

    Piccart-Gebhart M, Holmes A, de Azambuja E et al.. The association between event-free survival and pathological complete response to neoadjuvant lapatinib, trastuzumab or their combination in HER2-positive breast cancer. Survival follow-up analysis of the NeoALTTO study (BIG 1-06). [abstract]. Presented at the 2013 San Antonio Breast Cancer Symposium; December 10-14, 2013; San Antonio, Texas. Abstract S1-01.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 66.

    Scheuer W, Friess T, Burtscher H et al.. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 2009;69:9330–9336.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 67.

    Baselga J, Cortes J, Im SA et al.. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC) [abstract]. Cancer Res 2012;72(24 Suppl):Abstract S5-1.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 68.

    Swain S, Kim S-B, Cortes J et al.. Confirmatory overall survival (OS) analysis of CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study with pertuzumab (P), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive first-line (1L) metastatic breast cancer (MBC) [abstract]. Cancer Res 2012;72(24 Suppl):Abstract P5-18-26.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 69.

    Schneeweiss A, Chia S, Hickish T et al.. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 2013;24:2278–2284.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 70.

    Gianni L, Pienkowski T, Im YH et al.. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13:25–32.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 71.

    Ellis MJ, Coop A, Singh B et al.. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001;19:3808–3816.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 72.

    Smith IE, Dowsett M, Ebbs SR et al.. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005;23:5108–5116.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 73.

    Bass SS, Lyman GH, McCann CR et al.. Lymphatic mapping and sentinel lymph node biopsy. Breast J 1999;5:288–295.

  • 74.

    Cox CE. Lymphatic mapping in breast cancer: combination technique. Ann Surg Oncol 2001;8:67S–70S.

  • 75.

    Cox CE, Nguyen K, Gray RJ et al.. Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS? Am Surg 2001;67:513–519.

  • 76.

    Krag D, Weaver D, Ashikaga T et al.. The sentinel node in breast cancer—a multicenter validation study. N Engl J Med 1998;339:941–946.

  • 77.

    Krag DN, Anderson SJ, Julian TB et al.. Primary outcome results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients [abstract]. J Clin Oncol 2010;28(Suppl 18):Abstract LBA505.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 78.

    Lyman GH, Giuliano AE, Somerfield MR et al.. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005;23:7703–7720.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 79.

    McMasters KM, Giuliano AE, Ross MI et al.. Sentinel-lymph-node biopsy for breast cancer—not yet the standard of care. N Engl J Med 1998;339:990–995.

  • 80.

    O’Hea BJ, Hill AD, El-Shirbiny AM et al.. Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center. J Am Coll Surg 1998;186:423–427.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 81.

    Veronesi U, Paganelli G, Viale G et al.. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003;349:546–553.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 82.

    Mansel RE, Fallowfield L, Kissin M et al.. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 2006;98:599–609.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 83.

    Cox CE, Salud CJ, Cantor A et al.. Learning curves for breast cancer sentinel lymph node mapping based on surgical volume analysis. J Am Coll Surg 2001;193:593–600.

  • 84.

    Dupont E, Cox C, Shivers S et al.. Learning curves and breast cancer lymphatic mapping: institutional volume index. J Surg Res 2001;97:92–96.

  • 85.

    Giuliano AE, Hawes D, Ballman KV et al.. Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA 2011;306:385–393.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 86.

    Degnim AC, Reynolds C, Pantvaidya G et al.. Nonsentinel node metastasis in breast cancer patients: assessment of an existing and a new predictive nomogram. Am J Surg 2005;190:543–550.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 87.

    Houvenaeghel G, Nos C, Giard S et al.. A nomogram predictive of non-sentinel lymph node involvement in breast cancer patients with a sentinel lymph node micrometastasis. Eur J Surg Oncol 2009;35:690–695.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 88.

    Katz A, Smith BL, Golshan M et al.. Nomogram for the prediction of having four or more involved nodes for sentinel lymph node-positive breast cancer. J Clin Oncol 2008;26:2093–2098.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 89.

    Kohrt HE, Olshen RA, Bermas HR et al.. New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients. BMC Cancer 2008;8:66.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 90.

    Scow JS, Degnim AC, Hoskin TL et al.. Assessment of the performance of the Stanford Online Calculator for the prediction of nonsentinel lymph node metastasis in sentinel lymph node-positive breast cancer patients. Cancer 2009;115:4064–4070.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 91.

    van la Parra RF, Ernst MF, Bevilacqua JL et al.. Validation of a nomogram to predict the risk of nonsentinel lymph node metastases in breast cancer patients with a positive sentinel node biopsy: validation of the MSKCC breast nomogram. Ann Surg Oncol 2009;16:1128–1135.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 92.

    Werkoff G, Lambaudie E, Fondrinier E et al.. Prospective multicenter comparison of models to predict four or more involved axillary lymph nodes in patients with breast cancer with one to three metastatic sentinel lymph nodes. J Clin Oncol 2009;27:5707–5712.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 93.

    Giuliano AE, McCall L, Beitsch P et al.. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 2010;252:426–432; discussion 432-423.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 94.

    Giuliano AE, Hunt KK, Ballman KV et al.. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011;305:569–575.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 95.

    Axelsson CK, Mouridsen HT, Zedeler K. Axillary dissection of level I and II lymph nodes is important in breast cancer classification. The Danish Breast Cancer Cooperative Group (DBCG). Eur J Cancer 1992;28A:1415–1418.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 96.

    Kiricuta CI, Tausch J. A mathematical model of axillary lymph node involvement based on 1446 complete axillary dissections in patients with breast carcinoma. Cancer 1992;69:2496–2501.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 97.

    Fisher B, Redmond C, Fisher ER et al.. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985;312:674–681.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 98.

    Hellman S. Stopping metastases at their source. N Engl J Med 1997;337:996–997.

  • 99.

    Overgaard M, Hansen PS, Overgaard J et al.. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997;337:949–955.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 100.

    Overgaard M, Jensen MB, Overgaard J et al.. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 1999;353:1641–1648.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 101.

    Ragaz J, Olivotto IA, Spinelli JJ et al.. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst 2005;97:116–126.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 102.

    Recht A, Edge SB, Solin LJ et al.. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1539–1569.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 103.

    Huang EH, Tucker SL, Strom EA et al.. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol 2004;22:4691–4699.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 104.

    McGuire SE, Gonzalez-Angulo AM, Huang EH et al.. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys 2007;68:1004–1009.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 105.

    Clarke M, Collins R, Darby S et al.. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;366:2087–2106.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 106.

    Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol 2007;82:247–253.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 107.

    Whelan TJ, Olivotto I, Ackerman I et al.. NCIC-CTG MA.20: an intergroup trial of regional nodal irradiation in early breast cancer [abstract]. J Clin Oncol 2011;29 (18 Suppl):Abstract LBA1003.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 108.

    Whelan TJ, Pignol JP, Levine MN et al.. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010;362:513–520.

  • 109.

    Group ST, Bentzen SM, Agrawal RK et al.. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 2008;371:1098–1107.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 110.

    Group ST, Bentzen SM, Agrawal RK et al.. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol 2008;9:331–341.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 111.

    Nielsen HM, Overgaard M, Grau C et al.. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. J Clin Oncol 2006;24:2268–2275.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 112.

    Ahmed S, Snelling A, Bains M, Whitworth IH. Breast reconstruction. BMJ 2005;330:943–948.

  • 113.

    Edlich RF, Winters KL, Faulkner BC et al.. Advances in breast reconstruction after mastectomy. J Long Term Eff Med Implants 2005;15:197–207.

  • 114.

    Pennington DG. Breast reconstruction after mastectomy: current state of the art. ANZ J Surg 2005;75:454–458.

  • 115.

    Chang DW. Breast Reconstruction with Microvascular MS-TRAM and DIEP Flaps. Arch Plast Surg 2012;39:3–10.

  • 116.

    Garcia-Etienne CA, Cody Iii HS 3rd, Disa JJ et al.. Nipple-sparing mastectomy: initial experience at the Memorial Sloan-Kettering Cancer Center and a comprehensive review of literature. Breast J 2009;15:440–449.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 117.

    Petit JY, Veronesi U, Orecchia R et al.. Nipple sparing mastectomy with nipple areola intraoperative radiotherapy: one thousand and one cases of a five years experience at the European institute of oncology of Milan (EIO). Breast Cancer Res Treat 2009;117:333–338.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 118.

    Yueh JH, Houlihan MJ, Slavin SA et al.. Nipple-sparing mastectomy: evaluation of patient satisfaction, aesthetic results, and sensation. Ann Plast Surg 2009;62:586–590.

  • 119.

    Chung AP, Sacchini V. Nipple-sparing mastectomy: where are we now? Surg Oncol 2008;17:261–266.

  • 120.

    Gerber B, Krause A, Dieterich M et al.. The oncological safety of skin sparing mastectomy with conservation of the nipple-areola complex and autologous reconstruction: an extended follow-up study. Ann Surg 2009;249:461–468.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 121.

    Mallon P, Feron JG, Couturaud B et al.. The role of nipple-sparing mastectomy in breast cancer: a comprehensive review of the literature. Plast Reconstr Surg 2013;131:969–984.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 122.

    Piper M, Peled AW, Foster RD et al.. Total skin-sparing mastectomy: a systematic review of oncologic outcomes and postoperative complications. Ann Plast Surg, in press.

  • 123.

    Toth BA, Forley BG, Calabria R. Retrospective study of the skin-sparing mastectomy in breast reconstruction. Plast Reconstr Surg 1999;104:77–84.

  • 124.

    Carlson GW, Styblo TM, Lyles RH et al.. The use of skin sparing mastectomy in the treatment of breast cancer: the Emory experience. Surg Oncol 2003;12:265–269.

  • 125.

    Downes KJ, Glatt BS, Kanchwala SK et al.. Skin-sparing mastectomy and immediate reconstruction is an acceptable treatment option for patients with high-risk breast carcinoma. Cancer 2005;103:906–913.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 126.

    Foster RD, Esserman LJ, Anthony JP et al.. Skin-sparing mastectomy and immediate breast reconstruction: a prospective cohort study for the treatment of advanced stages of breast carcinoma. Ann Surg Oncol 2002;9:462–466.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 127.

    Medina-Franco H, Vasconez LO, Fix RJ et al.. Factors associated with local recurrence after skin-sparing mastectomy and immediate breast reconstruction for invasive breast cancer. Ann Surg 2002;235:814–819.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 128.

    Newman LA, Kuerer HM, Hunt KK et al.. Presentation, treatment, and outcome of local recurrence afterskin-sparing mastectomy and immediate breast reconstruction. Ann Surg Oncol 1998;5:620–626.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 129.

    Kronowitz SJ, Robb GL. Radiation therapy and breast reconstruction: a critical review of the literature. Plast Reconstr Surg 2009;124:395–408.

  • 130.

    Tran NV, Chang DW, Gupta A et al.. Comparison of immediate and delayed free TRAM flap breast reconstruction in patients receiving postmastectomy radiation therapy. Plast Reconstr Surg 2001;108:78–82.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 131.

    Mehta VK, Goffinet D. Postmastectomy radiation therapy after TRAM flap breast reconstruction. Breast J 2004;10:118–122.

  • 132.

    Clough KB, Kaufman GJ, Nos C et al.. Improving breast cancer surgery: a classification and quadrant per quadrant atlas for oncoplastic surgery. Ann Surg Oncol 2010;17:1375–1391.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 133.

    Anderson BO, Masetti R, Silverstein MJ. Oncoplastic approaches to partial mastectomy: an overview of volume-displacement techniques. Lancet Oncol 2005;6:145–157.

  • 134.

    Huemer GM, Schrenk P, Moser F et al.. Oncoplastic techniques allow breast-conserving treatment in centrally located breast cancers. Plast Reconstr Surg 2007;120:390–398.

  • 135.

    Kaur N, Petit JY, Rietjens M et al.. Comparative study of surgical margins in oncoplastic surgery and quadrantectomy in breast cancer. Ann Surg Oncol 2005;12:539–545.

  • 136.

    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Peto R, Davies C et al.. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012;379:432–444.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 137.

    Loprinzi CL, Thome SD. Understanding the utility of adjuvant systemic therapy for primary breast cancer. J Clin Oncol 2001;19:972–979.

  • 138.

    Ravdin PM, Siminoff LA, Davis GJ et al.. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001;19:980–991.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 139.

    Muss HB, Berry DA, Cirrincione CT et al.. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 2009;360:2055–2065.

  • 140.

    Olivotto IA, Bajdik CD, Ravdin PM et al.. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 2005;23:2716–2725.

  • 141.

    Loprinzi CL, Ravdin PM. Decision-making for patients with resectable breast cancer: individualized decisions for and by patients and their physicians. J Natl Compr Canc Netw 2003;1:189–196.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 142.

    Cooke T, Reeves J, Lanigan A, Stanton P. HER2 as a prognostic and predictive marker for breast cancer. Ann Oncol 2001;12(Suppl 1):23–28.

  • 143.

    Paik S, Bryant J, Park C et al.. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998;90:1361–1370.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 144.

    Paik S, Bryant J, Tan-Chiu E et al.. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 2000;92:1991–1998.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 145.

    Piccart MJ, Di Leo A, Hamilton A. HER2. a ‘predictive factor’ ready to use in the daily management of breast cancer patients? Eur J Cancer 2000;36:1755–1761.

  • 146.

    Pritchard KI, Shepherd LE, O’Malley FP et al.. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006;354:2103–2111.

  • 147.

    Thor AD, Berry DA, Budman DR et al.. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998;90:1346–1360.

  • 148.

    Dressler LG, Berry DA, Broadwater G et al.. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol 2005;23:4287–4297.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 149.

    Joensuu H, Kellokumpu-Lehtinen Pl, Bono P et al.. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809–820.

  • 150.

    Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al.. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659–1672.

  • 151.

    Goldhirsch A, Piccart-Gebhart M, Procter M et al.. HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up. Cancer Res 2012;72:S5–2.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 152.

    Romond E, Perez E, Bryant J et al.. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673–1684.

  • 153.

    Romond E, Suman V, Jeong JH et al.. Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831. Cancer Res 2012;72(24 Suppl):S5.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 154.

    Slamon D, Eiermann W, Robert N et al.. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365:1273–1283.

  • 155.

    Cobleigh MA, Vogel CL, Tripathy D et al.. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639–2648.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 156.

    Slamon DJ, Leyland-Jones B, Shak S et al.. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783–792.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 157.

    Vogel CL, Cobleigh MA, Tripathy D et al.. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719–726.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 158.

    Jeffrey SS, Lonning PE, Hillner BE. Genomics-based prognosis and therapeutic prediction in breast cancer. J Natl Compr Canc Netw 2005;3:291–300.

  • 159.

    Perou CM, Jeffrey SS, van de Rijn M et al.. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A 1999;96:9212–9217.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 160.

    Sorlie T, Perou CM, Tibshirani R et al.. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869–10874.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 161.

    Sorlie T, Tibshirani R, Parker J et al.. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418–8423.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 162.

    Paik S, Shak S, Tang G et al.. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817–2826.

  • 163.

    Paik S, Tang G, Shak S et al.. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726–3734.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 164.

    Fan C, Oh DS, Wessels L et al.. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006;355:560–569.

  • 165.

    Wang Y, Klijn JG, Zhang Y et al.. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005;365:671–679.

  • 166.

    Glas AM, Floore A, Delahaye LJ et al.. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 2006;7:278.

  • 167.

    van de Vijver MJ, He YD, van’t Veer LJ et al.. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999–2009.

  • 168.

    van ‘t Veer LJ, Dai H, van de Vijver MJ et al.. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530–536.

  • 169.

    Knauer M, Mook S, Rutgers EJ et al.. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat 2010;120:655–661.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 170.

    Kunz G. Use of a genomic test (MammaPrint) in daily clinical practice to assist in risk stratification of young breast cancer patients. Arch Gynecol Obstet 2011;283:597–602.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 171.

    Ishitobi M, Goranova TE, Komoike Y et al.. Clinical utility of the 70-gene MammaPrint profile in a Japanese population. Jpn J Clin Oncol 2010;40:508–512.

  • 172.

    Mook S, Knauer M, Bueno-de-Mesquita JM et al.. Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature. Ann Surg Oncol 2010;17:1406–1413.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 173.

    A phase III, randomized clinical trial of standard adjuvant endocrine therapy +/-chemotherapy in patients with 1-3 positive nodes, hormone receptor-positive and HER2-negative breast cancer with recurence score (RS) of 25 or less. RXPONDER: a clinical trial RX for positive node, endocrine responsive breast cancer. ClinicalTrials.govidentifier: NCT01272037.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 174.

    MINDACT (Microarray In Node-Negative and 1 to 3 positive lymph node disease may avoid chemotherapy): a prospective, randomized study comparing the 70-gene signature with the common clinical-pathological criteria in selecting patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes. ClinicalTrials.govidentifier: NCT00433589.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 175.

    Albain KS, Barlow WE, Shak S et al.. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010;11:55–65.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 176.

    Hormone therapy with or without combination chemotherapy in treating women who have undergone surgery for node-negative breast cancer (The TAILORx Trial). ClinicalTrials.govidentifier: NCT00310180.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 177.

    Swain SM, Wilson JW, Mamounas EP et al.. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. J Natl Cancer Inst 2004;96:516–523.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 178.

    Berry DA, Cirrincione C, Henderson IC et al.. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006;295:1658–1667.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 179.

    Albain KS, Barlow WE, Ravdin PM et al.. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009;374:2055–2063.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 180.

    Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 1998;351:1451–1467.

  • 181.

    Arpino G, Green SJ, Allred DC et al.. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res 2004;10:5670–5676.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 182.

    Berry DA, Muss HB, Thor AD et al.. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol 2000;18:3471–3479.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 183.

    De Laurentiis M, Arpino G, Massarelli E et al.. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 2005;11:4741–4748.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 184.

    Eppenberger-Castori S, Kueng W, Benz C et al.. Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay. J Clin Oncol 2001;19:645–656.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 185.

    Knoop AS, Bentzen SM, Nielsen MM et al.. Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J Clin Oncol 2001;19:3376–3384.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 186.

    Mass R. The role of HER-2 expression in predicting response to therapy in breast cancer. Semin Oncol 2000;27:46–52.

  • 187.

    Paik S, Shak S, Tang G et al.. Expression of the 21 genes in the recurrence score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer [abstract]. J Clin Oncol 2005;23(Suppl 16):Abstract 510.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 188.

    Pegram MD, Pauletti G, Slamon DJ. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 1998;52:65–77.

  • 189.

    Dowsett M, Allred C, Knox J et al.. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 2008;26:1059–1065.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 190.

    Early Breast Cancer Trialists’ Collaborative G, Davies C, Godwin J et al.. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011;378:771–784.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 191.

    Early Breast Cancer Trialists’ Collaborative G. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687–1717.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 192.

    Davies C, Pan H, Godwin J et al.. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013;381:805–816.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 193.

    Gray R, Rea D, Handley K et al.. aTTom (adjuvant Tamoxifen— To offer more?): randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer—preliminary results [abstract]. J Clin Oncol 2008;(15 Suppl):Abstract 513.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 194.

    Pritchard KI. Ovarian suppression/ablation in premenopausal ER-positive breast cancer patients. Issues and recommendations. Oncology (Williston Park) 2009;23:27–33.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 195.

    Puhalla S, Brufsky A, Davidson N. Adjuvant endocrine therapy for premenopausal women with breast cancer. Breast 2009;18(Suppl 3):S122–130.

  • 196.

    Tan SH, Wolff AC. The role of ovarian ablation in the adjuvant therapy of breast cancer. Curr Oncol Rep 2008;10:27–37.

  • 197.

    Cuzick J, Ambroisine L, Davidson N et al.. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007;369:1711–1723.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 198.

    Davidson NE, O’Neill AM, Vukov AM et al.. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol 2005;23:5973–5982.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 199.

    Ejlertsen B, Mouridsen HT, Jensen MB et al.. Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer. J Clin Oncol 2006;24:4956–4962.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 200.

    Goel S, Sharma R, Hamilton A, Beith J. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Cochrane Database Syst Rev 2009:CD004562.

  • 201.

    Kaufmann M, Jonat W, Blamey R et al.. Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer 2003;39:1711–1717.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 202.

    Schmid P, Untch M, Wallwiener D et al.. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate). Anticancer Res 2002;22:2325–2332.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 203.

    Thomson CS, Twelves CJ, Mallon EA, Leake RE. Adjuvant ovarian ablation vs CMF chemotherapy in premenopausal breast cancer patients: trial update and impact of immunohistochemical assessment of ER status. Breast 2002;11:419–429.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 204.

    von Minckwitz G, Graf E, Geberth M et al.. CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93). Eur J Cancer 2006;42:1780–1788.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 205.

    Castiglione-Gertsch M, O’Neill A, Price KN et al.. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst 2003;95:1833–1846.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 206.

    Roche H, Fumoleau P, Spielmann M et al.. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 2006;24:5664–5671.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 207.

    Boccardo F, Rubagotti A, Amoroso D et al.. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J Clin Oncol 2000;18:2718–2727.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 208.

    Coombes RC, Kilburn LS, Snowdon CF et al.. Survival and safety of exemestane versus tamoxifen after 2-3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007;369:559–570.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 209.

    Kaufmann M, Jonat W, Hilfrich J et al.. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol 2007;25:2664–2670.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 210.

    Goss PE, Ingle JN, Martino S et al.. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262–1271.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 211.

    Forbes JF, Cuzick J, Buzdar A et al.. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9:45–53.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 212.

    Thurlimann B, Keshaviah A, Coates AS et al.. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747–2757.

  • 213.

    Baum M, Budzar AU, Cuzick J et al.. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131–2139.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 214.

    Howell A, Cuzick J, Baum M et al.. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365:60–62.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 215.

    Duffy S, Jackson TL, Lansdown M et al.. The ATAC (’Arimidex’, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. Hum Reprod 2006;21:545–553.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 216.

    Fallowfield L, Cella D, Cuzick J et al.. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer trial. J Clin Oncol 2004;22:4261–4271.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 217.

    Eastell R, Adams JE, Coleman RE et al.. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 2008;26:1051–1057.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 218.

    Dowsett M, Cuzick J, Howell A, Jackson I. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘Arimidex and tamoxifen alone or in combination’ (ATAC) trial. Br J Cancer 2001;85:317–324.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 219.

    Buzdar AU, Guastalla JP, Nabholtz JM et al.. Impact of chemotherapy regimens prior to endocrine therapy: results from the ATAC (anastrozole and tamoxifen, alone or in combination) trial. Cancer 2006;107:472–480.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 220.

    Mouridsen H, Keshaviah A, Coates AS et al.. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. J Clin Oncol 2007;25:5715–5722.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 221.

    Rabaglio M, Sun Z, Price KN et al.. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol 2009;20:1489–1498.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 222.

    Mouridsen H, Giobbie-Hurder A, Goldhirsch A et al.. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009;361:766–776.

  • 223.

    Boccardo F, Rubagotti A, Puntoni M et al.. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 2005;23:5138–5147.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 224.

    Boccardo F, Rubagotti A, Guglielmini P et al.. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol 2006;17(Suppl 7):10–14.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 225.

    Coombes RC, Hall E, Gibson LJ et al.. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081–1092.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 226.

    Jakesz R, Jonat W, Gnant M et al.. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366:455–462.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 227.

    Jonat W, Gnant M, Boccardo F et al.. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol 2006;7:991–996.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 228.

    van de Velde CJ, Rea D, Seynaeve C et al.. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 2011;377:321–331.

  • 229.

    Goss PE, Ingle JN, Martino S et al.. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793–1802.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 230.

    Goss PE, Ingle JN, Pater JL et al.. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 2008;26:1948–1955.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 231.

    Ingle JN, Tu D, Pater JL et al.. Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Ann Oncol 2008;19:877–882.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 232.

    Perez EA, Josse RG, Pritchard KI et al.. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006;24:3629–3635.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 233.

    Whelan TJ, Goss PE, Ingle JN et al.. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 2005;23:6931–6940.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 234.

    Jakesz R, Greil R, Gnant M et al.. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst 2007;99:1845–1853.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 235.

    Dowsett M, Cuzick J, Ingle J et al.. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010;28:509–518.

  • 236.

    Smith IE, Dowsett M, Yap YS et al.. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol 2006;24:2444–2447.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 237.

    Yu B, Douglas N, Ferin MJ et al.. Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy. Cancer 2010;116:2099–2105.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 238.

    Dowsett M, Nielsen TO, A’Hern R et al.. Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 2011;103:1656–1664.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 239.

    Dowsett M, Smith IE, Ebbs SR et al.. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007;99:167–170.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 240.

    The Human Cytochrome P450 (CYP) Allele Nomenclature Database. Available at: http://www.cypalleles.ki.se/. Accessed March 7, 2014.

  • 241.

    Schroth W, Goetz MP, Hamann U et al.. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009;302:1429–1436.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 242.

    Leyland-Jones B, Regan M, Bouzyk M et al.. Outcome according to CYP2D6 genotype among postmenopausal women with endocrine-responsive early invasive breast cancer randomized in the BIG 1-98 trial [abstract]. Cancer Res 2010;70(24 Suppl):Abstract S1-8.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 243.

    Rae J, Drury S, Hayes D et al.. Lack of correlation between gene variants in tamoxifen metabolizing enymes with primary endpoints in the ATAC trial [abstract]. Cancer Res 2010;70(24 Suppl):Abstract S1-7.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 244.

    Higgins MJ, Stearns V. Pharmacogenetics of endocrine therapy for breast cancer. Annu Rev Med 2011;62:281–293.

  • 245.

    Visvanathan K, Chlebowski RT, Hurley P et al.. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 2009;27:3235–3258.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 246.

    Erban JK, Lau J. On the toxicity of chemotherapy for breast cancer—the need for vigilance. J Natl Cancer Inst 2006;98:1096–1097.

  • 247.

    Henderson I, Berry D, Demetri G et al.. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976–983.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 248.

    Mamounas E, Bryant J, Lembersky B et al.. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005;23:3686–3696.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 249.

    Citron ML, Berry DA, Cirrincione C et al.. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431–1439.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 250.

    Sparano JA, Wang M, Martino S et al.. Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node positive or high risk node negative breast cancer [abstract]. Presented at the 28th Annual San Antonio Breast Cancer Symposium; December 8-11, 2005; San Antonio, Texas. Abstract 48.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 251.

    Sparano JA, Wang M, Martino S et al.. Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in operable breast cancer: results of Intergroup trial E1199 [abstract]. J Clin Oncol 2007;25(Suppl 18):Abstract 516.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 252.

    Sparano J, Wang M, Martino S et al.. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008;358:1663–1671.

  • 253.

    Jones S, Holmes FA, O’Shaughnessy J et al.. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research trial 9735. J Clin Oncol 2009;27:1177–1183.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 254.

    Bang SM, Heo DS, Lee KH et al.. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma. Cancer 2000;89:2521–2526.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 255.

    Fisher B, Anderson S, Tan-Chiu E et al.. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 2001;19:931–942.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 256.

    Fisher B, Brown AM, Dimitrov NV et al.. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990;8:1483–1496.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 257.

    Fisher B, Anderson S, Wickerham DL et al.. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 1997;15:1858–1869.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 258.

    Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 1998;352:930–942.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 259.

    Wood WC, Budman DR, Korzun AH et al.. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994;330:1253–1259.

  • 260.

    Menard S, Valagussa P, Pilotti S et al.. Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. J Clin Oncol 2001;19:329–335.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 261.

    Muss HB, Thor AD, Berry DA et al.. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994;330:1260–1266.

  • 262.

    Watanabe T, Kuranami M, Inoue K et al.. Phase III trial comparing 4-cycle doxorubicin plus cyclophosphamide followed by 4-cycle taxan with 8-cycle taxan as adjuvant therapy for node-positive breast cancer: results of N-SAS-BC02 trial [abstract]. J Clin Oncol 2009;27(Suppl 15):Abstract 516.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 263.

    Levine M, Pritchard K, Bramwell V et al.. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol 2005;23:5166–5170.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 264.

    Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 Randomized Trial. J Clin Oncol 2001;19:602–611.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 265.

    Piccart MJ, Di Leo A, Beauduin M et al.. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol 2001;19:3103–3110.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 266.

    Ellis P, Barrett-Lee P, Johnson L et al.. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet 2009;373:1681–1692.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 267.

    Martin M, Rodriguez-Lescure A, Ruiz A et al.. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. J Natl Cancer Inst 2008;100:805–814.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 268.

    Martin M, Pienkowski T, Mackey J et al.. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352:2302–2313.

  • 269.

    Swain SM, Jeong JH, Geyer CE et al.. NSABP B-30: definitive analysis of patient outcome from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer [abstract]. Cancer Res 2009;69(Suppl 1):Abstract 75.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 270.

    Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med 2005;353:1652–1654.

  • 271.

    Joensuu H, Bono P, Kataja V et al.. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol 2009;27:5685–5692.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 272.

    Perez EA, Romond EH, Suman VJ et al.. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011;29:3366–3373.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 273.

    Gianni L, Dafni U, Gelber RD et al.. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 2011;12:236–244.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 274.

    Perez EA, Suman VJ, Davidson NE et al.. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008;26:1231–1238.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 275.

    Tan-Chiu E, Yothers G, Romond E et al.. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23:7811–7819.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 276.

    Geyer CE Jr, Bryant JL, Romond EH et al.. Update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)->paclitaxel (T) vs. AC->T with trastuzumab (H) [abstract]. J Clin Oncol 2006;24(Suppl 18):Abstract 581.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 277.

    Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 2007;25:3525–3533.

  • 278.

    Smith I, Procter M, Gelber RD et al.. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29–36.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 279.

    Spielmann M, Roché H, Delozier T et al.. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 2009;27:6129–6134.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 280.

    Chia S, Norris B, Speers C et al.. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol 2008;26:5697–5704.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 281.

    Gonzalez-Angulo AM, Litton JK, Broglio KR et al.. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 2009;27:5700–5706.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 282.

    O’Sullivan C, Holmes E, Spielmann M et al.. The prognosis of small HER2+ breast cancers: a meta-analysis of the randomized trastuzumab trials [abstract]. Presented at the 2013 San Antonio Breast Cancer Symposium; December 10-14, 2013; San Antonio, Texas. Abstract S6-03

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 283.

    Zhou Q, Yin W, Du Y, Lu J. For or against adjuvant trastuzumab for pT1a-bN0M0 breast cancer patients with HER2-positive tumors: a meta-analysis of published literatures. PLoS One 2014;9:e83646.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 284.

    Tolaney S, Barry W, Dang C et al.. A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC) [abstract]. Presented at the 2013 San Antonio Breast Cancer Symposium; December 10-14, 2013; San Antonio, Texas. Abstract S1-04.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 285.

    Norris B, Chia S, Cheang M et al.. Poor 10 yr breast cancer specific survival and relapse free survival for HER2 positive T1N0 tumors [abstract]. Presented at the 29th San Antonio Breast Cancer Symposium; December 14-17, 2006; San Antonio, Texas. Abstract 2031.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 286.

    Curigliano G, Viale G, Bagnardi V et al.. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 2009;27:5693–5699.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 287.

    Perez EA, Romond EH, Suman VJ et al.. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer [abstract]. J Clin Oncol 2007;25(Suppl 18):Abstract 512.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 288.

    Untch M, Gelber RD, Jackisch C et al.. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 2008;19:1090–1096.

  • 289.

    von MG, Baselga J, Bradbury I et al.. Adjuvant Pertuzumab and Herceptin IN IniTial TherapY of Breast Cancer: APHINITY (BIG 4-11/BO25126/TOC4939g) [abstract]. Cancer Res 2011;71(Suppl 24):Abstract OT1-02-04.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 290.

    A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast ClinicalTrials.govidentifier: NCT01358877.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 291.

    Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators. JAMA 1994;271:1587–1592.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 292.

    Rosselli Del Turco M, Palli D, Cariddi A et al.. Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up. JAMA 1994;271:1593–1597.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 293.

    Smith TJ, Davidson NE, Schapira DV et al.. American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. J Clin Oncol 1999;17:1080–1082.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 294.

    Bast RC, Ravdin P, Hayes DF et al.. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1865–1878.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 295.

    Kirova YM, Stoppa-Lyonnet D, Savignoni A et al.. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur J Cancer 2005;41:2304–2311.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 296.

    Metcalfe K, Lynch HT, Ghadirian P et al.. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004;22:2328–2335.

  • 297.

    Pierce LJ, Levin AM, Rebbeck TR et al.. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 2006;24:2437–2443.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 298.

    ACOG committee opinion. No. 336: Tamoxifen and uterine cancer. Obstet Gynecol 2006;107:1475–1478.

  • 299.

    Loprinzi CL, Kugler JW, Sloan JA et al.. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356:2059–2063.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 300.

    Boekhout AH, Vincent AD, Dalesio OB et al.. Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2011;29:3862–3868.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 301.

    Kaplan M, Mahon S, Cope D et al.. Putting evidence into practice: evidence-based interventions for hot flashes resulting from cancer therapies. Clin J Oncol Nurs 2011;15:149–157.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 302.

    Bordeleau L, Pritchard KI, Loprinzi CL et al.. Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. J Clin Oncol 2010;28:5147–5152.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 303.

    Garber K. Tamoxifen pharmacogenetics moves closer to reality. J Natl Cancer Inst 2005;97:412–413.

  • 304.

    Jin Y, Desta Z, Stearns V et al.. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005;97:30–39.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 305.

    Henry NL, Stearns V, Flockhart DA et al.. Drug interactions and pharmacogenomics in the treatment of breast cancer and depression. Am J Psychiatry 2008;165:1251–1255.

  • 306.

    Ahern TP, Pedersen L, Cronin-Fenton DP et al.. No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications. Cancer Epidemiol Biomarkers Prev 2009;18:2562–2564.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 307.

    Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487–497.

  • 308.

    Li CI, Daling JR, Porter PL et al.. Relationship between potentially modifiable lifestyle factors and risk of second primary contralateral breast cancer among women diagnosed with estrogen receptor-positive invasive breast cancer. J Clin Oncol 2009;27:5312–5318.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 309.

    Pierce JP, Stefanick ML, Flatt SW et al.. Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity. J Clin Oncol 2007;25:2345–2351.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 310.

    Hickey M, Peate M, Saunders CM, Friedlander M. Breast cancer in young women and its impact on reproductive function. Human Reprod Update 2009;15:323–339.

  • 311.

    Moran MS, Colasanto JM, Haffty BG et al.. Effects of breast-conserving therapy on lactation after pregnancy. Cancer J 2005;11:399–403.

Copyright:
Copyright © 2014 by the National Comprehensive Cancer Network 2014
Page Numbers:
49
Article Category:
Research Article
Print Publication Date:
01 Apr 2014
Online Publication Date:
Apr 2014

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 10728 5504 453
PDF Downloads 2071 586 39
EPUB Downloads 0 0 0